Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up - What's Next?

Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $17.40, but opened at $17.87. Pulse Biosciences shares last traded at $18.04, with a volume of 23,965 shares trading hands.

Analyst Ratings Changes

Separately, StockNews.com raised shares of Pulse Biosciences to a "sell" rating in a report on Tuesday.

Pulse Biosciences Price Performance

The stock's 50-day simple moving average is $17.93 and its 200-day simple moving average is $16.66.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter in the prior year, the company earned ($0.19) earnings per share.

Insider Activity at Pulse Biosciences

In other news, CEO Burke Thomas Barrett sold 50,000 shares of the firm's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the transaction, the chief executive officer now directly owns 63,172 shares of the company's stock, valued at $1,100,456.24. This trade represents a 44.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert W. Duggan bought 55,256 shares of Pulse Biosciences stock in a transaction on Friday, December 13th. The shares were bought at an average cost of $17.18 per share, with a total value of $949,298.08. Following the acquisition, the director now directly owns 42,328,717 shares in the company, valued at approximately $727,207,358.06. This represents a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 71.50% of the stock is owned by company insiders.

Institutional Trading of Pulse Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of PLSE. State Street Corp boosted its position in shares of Pulse Biosciences by 17.8% during the 3rd quarter. State Street Corp now owns 461,333 shares of the company's stock valued at $8,092,000 after acquiring an additional 69,696 shares during the last quarter. Geode Capital Management LLC grew its position in Pulse Biosciences by 7.8% in the third quarter. Geode Capital Management LLC now owns 457,165 shares of the company's stock worth $8,020,000 after acquiring an additional 33,200 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Pulse Biosciences by 193.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company's stock valued at $2,598,000 after acquiring an additional 97,565 shares during the last quarter. Bank of New York Mellon Corp raised its position in Pulse Biosciences by 23.4% during the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company's stock valued at $570,000 after purchasing an additional 9,639 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Pulse Biosciences during the third quarter worth about $588,000. Institutional investors own 76.95% of the company's stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.